Clinical Study of Osimertinib Targeted Therapy for Advanced Non-Small Cell Lung Cancer
Objective To investigate the clinical efficacy of osimertinib targeted therapy for advanced non-small cell lung cancer(NSCLC).Methods A total of 113 patients with advanced NSCLC admitted to the oncology department of the hospital from January 2021 to December 2022 were selected and divided into the chemotherapy group(54 cases)and the targeted therapy group(referred to as the targeted group,59 cases)based on different treatment regimens.The patients in the chemotherapy group were given intravenous drip of Pemetrexed Disodium for Injection+Cisplatin for Injection,while the patients in the targeted group were given Osimertinib Mesylate Tablets orally.Results The disease control rate in the targeted group was 93.22%,which was significantly higher than 74.07%in the chemotherapy group(P<0.05).After treatment,the serum carcinoembryonic antigen(CEA),squamous cell carcinoma-antigen(SCC-Ag)and cytokeratin 19 fragment antigen 21-1(CYFRA21-1)levels in the two groups were significantly lower(P<0.05),and those in the targeted group were significantly better(P<0.05).After treatment,the T lymphocyte subgroup CD4+level in the targeted group was significantly higher,the CD8+level was significantly lower,and the CD4+/CD8+was significantly higher(P<0.05).The incidence of adverse reactions in the targeted group was 11.86%,which was significantly lower than 29.63%in the chemotherapy group(P<0.05).Conclusion Osimertinib targeted therapy can decrease the serum tumor cytokine level in patients with advanced NSCLC and has a slight effect on their immune function.
万方数据
维普
